tezacaftor drug used treatment cystic fibrosis cf people six years older mutation common type mutation cftr sold fixeddose combination ivacaftor brand name approved us fda combination elexacaftor tezacaftor ivacaftor sold us food drug administration fda approved combination elexacaftor tezacaftor tezacaftor acts corrector help folding presentation cftr protein cell surface improves function individuals evolve expand study findings published evolve trial analyzed tezacaftorivacaftor patients cystic fibrosis specifically homozygous evolve trial phase doubleblinded multicenter randomized placebocontrolled parallelgroup trial evaluated therapy combination tezacaftor ivacaftor patients patients randomized patients given either mg tezacaftor daily mg ivacaftor twice daily placebo combination drugs efficacious patients cystic fibrosis mutation adverse effects treatment groups us food drug administration fda granted application tezacaftor ivacaftor combination therapy orphan drug designation priority review granted approval symdeko vertex pharmaceuticals drug article relating respiratory system stub help wikipedia expanding ithttpsenwikipediaorgwikitezacaftor